谷飞;皮兴文;

• 1:湖北中医药大学鄂州市中医医院

摘要(Abstract)：

急性缺血性脑卒中(AIS)是指由于各种原因导致的脑组织局部供血不足所引起的神经功能性疾病,在AIS的治疗和二级预防中,利用抗血小板治疗是最常用的手段。替罗非班作为一种全新的抗血小板聚集药物,在心血管疾病应用中日渐成熟,但对于替罗非班在AIS静脉溶栓后的应用中仍存在一定争议。现将替罗非班在AIS静脉溶栓后的应用进展进行综述。

关键词(KeyWords)： 急性缺血性脑卒中;替罗非班;静脉溶栓;阿替普酶;抗血小板治疗

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 谷飞;皮兴文;

参考文献(References)：

• [1]WAHLGREN N,MOREIRA T,MICHEL P,et al.Mechanical thrombectomy in acute ischemic stroke:Consensus statement by ESO-Karolinska Stroke Update 2014/2015,supported by ESO,ESMINT,ESNR and EAN[J].Int J Stroke,2016,11(1):134-147.DOI:10.1177/17474930-15609778.
• [2]GUNAL A,BASKURT F,BASKURT Z.The effect of emotional distress on functional outcomes in acute stroke patients[J].Niger J Clin Pract,2019,22(11):1583-1589.DOI:10.4103/njcp.njcp_584_18.
• [3]MORRIS D C.Thrombolysis 3 to 4.5 Hours after Acute Ischemic Stroke[J].N Engl J Med,2008,359(26):2841.DOI:10.1056/NEJMc082179.
• [4]RUBIERAM,ALVAREZSABIN J,RIBO M,et al.Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke[J].Stroke,2005,36(7):1452-1456.DOI:10.1161/01.STR.0000170711.43405.81
• [5]YU W M,ABDUL-RAHIM A H,CAMERON A C,et al.The incidence and associated factors of early neurological deterioration after thrombolysis:results from SITS registry[J].Stroke,2020,51(9):2705-2714.DOI:10.1161/STROKEAHA.119.028287.
• [6]BHATIA R,HILL M D,SHOBHA N,et al.Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke:real-world experience and a call for action[J].Stroke,2010,41(10):2254-2258.DOI:10.1161/STROKEAHA.110.592535.
• [7]常建军,李浩,李春生,等.阿替普酶静脉溶栓治疗急性脑梗死及出血转化的影响因素[J].中国实用神经疾病杂志,2019,22(9):948-953.DOI:10.12083/SYSJ.2019.09.276.
• [8]BARRETO A D,DROTTA J C.Randomized multicenter trial of ARTSS-2(argatroban with recombinant tissue plasminogen activator for acute stroke)[J].Stroke,2017,48(6):1608-1616.DOI:10.1161/STROKEAHA.117.018294.
• [9]SHATTIL S J,NEWMAN P J.Integrins:dynamic scaffolds for adhesion and signaling in platelets[J].Blood,2004,104(6):1606-1615.DOI:10.1182/blood-2004-04-1257.
• [10]ZINKSTOK S M,ROOS Y B.Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke:a randomised controlled trial[J].The Lancet,2012,380(9843):731-737.DOI:10.1016/S0140-6736(12)60949-0.
• [11]MANDAVA P,THIAGARAJAN P,KENT T A.Glycoprotein IIb/IIIa antagonists in acute ischaemic stroke:current status and future directions[J].Drugs,2008,68(8):1019-1028.DOI:10.2165/00003495-200868080-00001.
• [12]HARMON C,KING S,SHORT M.Glycoprotein IIb/IIIa Inhibitors:The Resurgence of Tirofiban[J].Vasc Pharmacol,2016,78:10-16.DOI:10.1016/j.vph.2015.07.008.
• [13]PRAKASH R,CARMICHAEL S T.Blood-brain barrier breakdown and neovascularization processes after stroke and traumatic brain injury[J].Curr Opin Neurol,2015,28(6):556-56.DOI:10.1097/WCO.0000000000000248.
• [14]GELDERBLOM M,LEYPOLDT F,STEINBACHK,et al.Temporal and spatial dynamics of cerebral immune cell accumulation in stroke[J].Stroke,2009,40(5):1849-1857.DOI:10.1161/STROKEAHA.108.534503.
• [15]LADECOLAC,ANRATHERJ.Theimmunologyof stroke:from mechanisms to translation[J].Nat Med,2011,17(7):796-808.DOI:10.1038/nm.2399.
• [16]ZINKSTOK S M,VERMEULEN M,STAM J,et al.Antiplatelet therapy in combination with rt-PA thrombolysis in ischemic stroke(ARTIS):rationale and design of a randomized controlled trial[J].Cerebrovasc Dis,2010,29(1):79-81.DOI:10.1159/000256651.
• [17]HUO X,YANG M,MA N,et al.Safety and efficacy of tirofiban during mechanical thrombectomy for stroke patients with preceding intravenous thrombolysis[J].Clin Interv Aging,2020(15):1241-1248.DOI:10.2147/CIA.S238769.
• [18]KUMAR A,HRERMANN H C.Tirofiban:an investigational platelet glycoprotein IIb/IIIa receptor antagonist[J].Expert Opin Investig Drugs,1997,6(9):1257-1267.DOI:10.1517/13543784.6.9.1257.
• [19]KANG D H,KIM Y W,HWANG Y H,et al.Instant reocclusion following mechanical thrombectomy of in situ thromboocclusion and the role of low-dose intra-arterial tirofiban[J].Cerebrovasc Dis,2014,37(5):350-355.DOI:10.1159/000362435.
• [20]SCHWARZ M,MEADE G,STOLL P,et al.Conformation-specific blockade of the integrin GPIIb/IIIa:a novel antiplatelet strategy that selectively targets activated platelets[J].Circ Res,2006,99(1):25-33.DOI:10.1161/01.RES.0000232317.84122.0c.
• [21]VAN’T HOF A W,TEN BERG J,HEESTERMANS T,et al.Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty(On-TIME 2):a multicenter,double-blind,randomised controlled trial[J].Lancet,2008,372(9638):537-546.DOI:10.1016/S0140-6736(08)61235-0.
• [22]VALGIMIGLI M,BIONDI-ZOCCAI G,TEBAL-DI M,et al.Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention:a meta-analysis of randomized trials[J].Eur Heart,2010,31(1):35-49.DOI:10.1093/eurheartj/ehp376.
• [23]ISHIKAWA T,SHIMIZU M,KOHARA S,et al.Appearance of wbc platelet complex in acute ischemic stroke,predominantly in atherothrombotic infarction[J].J Atheroscler Thromb,2012,19(5):494-501.DOI:10.5551/jat.10637.
• [24]COLLER B S.Anti-GPⅡb/Ⅲa drugs:current strategies and future directions[J].Thromb Haemost,2001,86(1):427-443.DOI:10.1055/s-0037-1616241.
• [25]KUMAR A,HERRMANN H C.Tirofiban:an investigational platelet glycoprotein IIb/IIIa receptor antagonist[J].Expert Opin Investig Drugs,1997,6(9):1257-1267.DOI:10.1517/13543784.6.9.1257.
• [26]YI T Y,CHEN W H,WU Y M,et al.Special Endovascular Treatment for Acute Large Artery Occlusion Resulting From Atherosclerotic Disease[J].World Neurosurg,2017,103(7):65-72.DOI:10.1016/j.wneu.2017.03.108.
• [27]STRAUB S.Systemic Thrombolysis With Recombinant Tissue Plasminogen Activator and Tirofiban in Acute Middle Cerebral Artery Occlusion[J].Stroke,2004,35(3):705-709.DOI:10.1161/01.STR.0000117094.41638.EE.
• [28]LI W,LIN L,ZHANG M,et al.Safety and preliminary efficacy of early tirofiban treatment after alteplase in acute ischemic stroke patients[J].Stroke,2016,47(10):2649-2651.DOI:10.1161/STROKEAHA.116.014413.
• [29]RUBIERA M,ALVAREZ-SABIN J,RIBO M,et al.Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke[J].Stroke,2005,36(7):1452-1456.DOI:10.1161/01.STR.0000170711.43405.81.
• [30]TORGANO G,ZECCA B,MONZANI V,et al.Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke:a double-blind randomized trial[J].Cerebrovasc Dis,2010,29(3):275-281.DOI:10.1159/000275503.
• [31]PAN X,ZHENG D,ZHENG Y,et al.Safety and efficacy of tirofiban combined with endovascular treatment in acute ischaemic stroke[J].Eur J Neurol,2019,21(6):253-258.DOI:10.1111/ene.13946.
• [32]LIN L,LI W,LIU C C,et al.Safety and preliminary efficacy of intravenous tirofiban in acute ischemic stroke patient without arterial occlusion on neurovascular imaging studies[J].Neurol Sci,2017,383:175-179.DOI:10.1016/j.jns.2017.10.041.
• [33]魏丽红,张燕,郑献召,等.替罗非班联合阿替普酶对超早期脑梗死患者缺血半暗带的影响[J].中国实用神经疾病杂志,2020,23(15):1328-1333.DOI:10.12083/SYSJ.2020.15.015.
• [34]KELLERT L,HAMETNER C,ROHDE S,et al.Endovascular stroke therapy:tirofiban is associated with risk of fatal intracerebral hemorrhage and poor outcome[J].Stroke,2013,44(5):1453-1455.DOI:10.1161/STROKEAHA.111.000502.
• [35]LI W,LIN L,ZHANG M,et al.Safety and Preliminary Efficacy of Early Tirofiban Treatment After Alteplase in Acute Ischemic Stroke Patients[J].Stroke,2016,47(10):2649-2651.DOI:10.1161/STROKEAHA.116.014413.
• [36]PHILIPPS J,THOMALLA G,GLAHN J,et al.Treatment of progressive stroke with tirofibanexperience in 35 patients[J].Cerebrovasc Dis,2009,28(5):435-438.DOI:10.1159/000235987.
• [37]JOVIN T G,CHAMORRO A,COBO E,et al.Thrombectomy within 8 hours after symptom onset in ischemic stroke[J].N Engl J Med,2015,372(24):2296-2306.DOI:10.1056/NEJMoa1503780.
• [38]KIM S H,KIM T G,KONG M H.Intra-arterial and Intravenous Tirofiban Infusion for Thromboembolism during Endovascular Coil Embolization of Cerebral Aneurysm[J].JKorean Neurosurg Soc,2017,60(5):518-526.DOI:10.3340/jkns.2016.1212.006.
• [39]SEITZ R J,HAMZAVI M,JUNGHANS U,et al.Thrombolysis with recombinant tissue plasminogen activator and tirofiban in stroke:Preliminary observations[J].Stroke,2003,34(8):1932-1935.DOI:10.1161/01.STR.0000080535.61188.A6.
• [40]SEITZ R J,MEISEL S,MOLL M,et al.The effect of combined thrombolysis with rt PA and tirofiban on ischemic brain lesions[J].Neurology,2004,62(11):2110-2112.DOI:10.1212/01.WNL.0000129480.17345.4A.
• [41]SEITZ R J,MEISLE S,MOLL M,et al.Partial rescue of the perfusion deficit area by thrombolysis[J].J Magn Reson Imaging,2005,22(2):199-205.DOI:10.1002/jmri.20366.
• [42]SEITZ R J,SIEBLER M.Platelet GPⅡb/Ⅲa receptor antagonists in human ischemic brain disease[J].Curr Vasc Pharmacol,2008,6(1):29-36.DOI:10.2174/157016108783331303.
• [43]SEITE R J,SUKIENNIK J,SIEBLER M.Outcome after systemic thrombolysis is predicted by age and stroke severity:An open label experience with recombinant tissue plasminogen activator and tirofiban[J].Neurol Int,2012,4(2):e9.DOI:10.4081/ni.2012.e9.
• [44]孙原,石秋艳,李艳玲,等.替罗非班治疗阿替普酶静脉溶栓后再闭塞的疗效观察[J].中国实用神经疾病杂志,2018,21(1):40-43.DOI:10.12083/SYSJ.2018.01.010.
• [45]WANG H,LI X,LIU C,et al.Effects of oral antiplatelet agents and tirofiban on functional outcomes of patients with non-disabling minor acute ischemic stroke[J].J Stroke Cerebrovasc Dis,2020,29(8):104829.DOI:10.1016/j.jstrokecerebrovasdis.2020.104829.
• [46]MITSIAS P D.Early neurological deterioration after intravenous thrombolysis:still no end in sight in the quest for understanding END[J].Stroke,2020,51(9):2615-2617.DOI:10.1161/STROKEAHA.120.030982.
• [47]郭耀强,白宏英,录海斌,等.HAT评分对急性脑梗死患者阿替普酶静脉溶栓后出血转化的预测[J].中国实用神经疾病杂志,2020,23(23):2092-2096.DOI:10.12083/SYSJ.2020.24.004.
• [48]LIU J,SHI Q,SUN Y,et al.Efficacy of tirofiban administered at different time points after intravenous thrombolytic therapy with alteplase in patients with acute ischemic stroke[J].J Stroke Cerebrovasc Dis,2019,28(4):1126-1132.DOI:10.1016/j.jstrokecerebrovasdis.2018.12.044.
• [49]贾晓涛,潘艳芳,雷辉,等.替罗非班在超溶栓时间窗、非大血管病变脑梗死治疗中的应用效果及对血管内皮功能的影响[J].中西医结合心脑血管病杂志,2021,19(10):1631-1633.DOI:10.12102/j.issn.1672-1349.2021.10.007.
• [50]PHILOPPS J,THOMALLA G,GLAHN J,et al.Treatment of progressive stroke with tirofiban-experience in 35 patients[J].Cerebrovasc Dis,2009,28(5):435-438.DOI:10.1159/000235987.
• [51]汪娜.不同剂量盐酸替罗非班对STEMI患者PCI术后治疗效果的比较[J].中国处方药,2021,19(7):141-144.DOI:10.3969/j.issn.1671-945X.2021.07.067.
• [52]ALEXANDER K P,CHEN A Y,NEWBY L K,et al.Sex differences in major bleeding with glycoproteinⅡb/Ⅲa inhibitors:results from the crusade(can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the acc/aha guidelines)initiative[J].Circulation,2006,114(13):1380-1387.DOI:10.1161/CIRCULATIONAHA.106.620815.
• [53]NETTERSHEIM F S,HOHMANN C,PFISTERR,et al.Severe tirofiban-induced thrombocytopenia and thrombotic microangiopathy after percutaneous coronary intervention[J].Dtsch Med Wochenschr,2019,144(2):456-459.DOI:10.1055/a-0787-6634.
• [54]YI Y H,YIN W J,GU Z C,et al.A simple clinical pre-procedure risk model for predicting thrombocytopenia associated with periprocedural use of tirofiban in patients undergoing percutaneous coronary intervention[J].Front Pharmacol,2018,9(7):1667-1676.DOI:10.3389/fphar.2018.01456.
• [55]SIEBLER M,HENNERICI M G,SCHNEIDERD,et al.Safety of tirofiban in acute ischemic stroke:the satis trial[J].Stroke,2011,42(9):2388-2392.DOI:10.1161/STROKEAHA.110.599662.
• [56]GIORDANO A,D’ANGELILLO A,ROMANOS,et al.Tirofiban induces VEGF production and stimulates migration and proliferation of endothelial cells[J].Vascul Pharmacol,2014,61(2/3):63-71.DOI:10.1016/j.vph.2014.04.002.
• [57]GAO H Q,XU S D,LI J R,et al.Tirofiban promotes the proliferation of human umbilical vein endothelial cells in vitro via enhanced vascular endothelial growth factor expression[J].Transplant Proc,2020,52(1):419-422.DOI:10.1016/j.transproceed.2019.10.007.